cais ghk cu Shop GHK-Cu Peptides While some technologies can give skin a temporary boost Support your skin’s natural collagen

The SURMOUNT-1 trial tested the ability of tirzepatide to produce weight loss in people with obesity who do not have diabetes

Sensorgrams were analyzed using a global fit to the 1:1 Langmuir binding model

In the head-to-head SURMOUNT-5 trial (NEJM, 2025), tirzepatide produced 20.2% body weight loss vs 13.7% for semaglutide at 72 weeks, with similar side-effect profiles

The approval was backed by results of a prespecified exploratory subgroup analysis by MMR status in the DUO-E Phase III trial where Imfinzi plus chemotherapy followed by Imfinzi monotherapy reduced the risk of disease progression or death by 58% versus chemo alone